Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

NextCure, Inc. NXTC

Healthcare  —  Biotechnology
5.08 (0.20) (3.79%) as of 25 Sep
Market cap
$25.4M
P/E
0.0×
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

NextCure, Inc. (NXTC) Business Profile

Updated before January 2025

Company Overview

NextCure, Inc. (NASDAQ: NXTC) is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative immunomedicines to treat cancer and other immune-related diseases. Founded in 2015 by Dr. Lieping Chen, a pioneer in immunotherapy, and headquartered in Beltsville, Maryland, NextCure leverages its proprietary FIND-IO™ platform to identify novel therapeutic targets. The company is led by a team of seasoned professionals, including Michael Richman, who serves as President and Chief Executive Officer. Richman brings decades of experience in the biotechnology and pharmaceutical industries, steering the company toward its mission of addressing unmet medical needs.

Core Business Segments

Immunomedicine Development

NextCure’s primary focus is on the development of immunomedicines that modulate the immune system to combat diseases. The company’s pipeline includes:

  • NC318: A first-in-class immunomedicine targeting Siglec-15 (S15), a novel immune checkpoint molecule. NC318 is currently in clinical trials for the treatment of advanced solid tumors.
  • NC410: A novel immunomedicine designed to block immune suppression by targeting the LAIR-1 pathway. NC410 is being evaluated for its potential to enhance immune responses in cancer patients.
  • NC762: An antibody targeting B7-H4, another immune checkpoint molecule, which is in early-stage clinical trials for cancer treatment.

Proprietary FIND-IO™ Platform

NextCure’s FIND-IO™ (Functional, Integrated, Next-generation Discovery of Immuno-oncology targets) platform is a cornerstone of its business. This proprietary technology enables the identification of novel immune pathways and targets, providing a competitive edge in the immunotherapy space.

Collaborative Partnerships

NextCure collaborates with leading academic institutions and research organizations to advance its pipeline. These partnerships enhance the company’s ability to discover and develop groundbreaking therapies.

Business Model

NextCure operates as a research-driven biopharmaceutical company. Its business model revolves around:

  1. Research and Development (R&D): A significant portion of the company’s resources is allocated to R&D activities, focusing on the discovery and clinical development of novel immunomedicines.
  2. Clinical Trials: NextCure conducts rigorous clinical trials to evaluate the safety and efficacy of its drug candidates.
  3. Collaborations and Licensing: The company generates revenue through strategic collaborations and licensing agreements with other biotech and pharmaceutical companies.
  4. Intellectual Property: NextCure protects its innovations through a robust portfolio of patents, ensuring exclusivity and competitive advantage.

Strategic Direction

NextCure aims to solidify its position as a leader in immunomedicine by:

  • Expanding its Pipeline: The company is committed to advancing its existing drug candidates while exploring new therapeutic targets using the FIND-IO™ platform.
  • Enhancing Clinical Development: NextCure plans to accelerate the clinical development of its lead candidates, including NC318, NC410, and NC762.
  • Fostering Collaborations: The company seeks to establish new partnerships with academic institutions and industry players to drive innovation.
  • Sustainability Goals: While not explicitly stated, NextCure’s focus on addressing unmet medical needs aligns with broader sustainability objectives in healthcare.

Competitive Landscape

NextCure operates in a highly competitive biopharmaceutical sector, facing competition from both established players and emerging startups. Key competitors include:

  • Merck & Co.: Known for its blockbuster immunotherapy drug Keytruda.
  • Bristol-Myers Squibb: A leader in immuno-oncology with products like Opdivo and Yervoy.
  • Regeneron Pharmaceuticals: Focused on innovative antibody-based therapies.
  • Smaller Biotech Firms: Companies like Arcus Biosciences and Surface Oncology also compete in the immunotherapy space.

Risk Factors

NextCure faces several risks that could impact its operations and financial performance:

  • Clinical Trial Risks: The success of the company’s drug candidates depends on the outcomes of clinical trials, which are inherently uncertain.
  • Regulatory Challenges: Obtaining regulatory approval for new therapies is a complex and time-consuming process.
  • Market Dependence: The company’s revenue is heavily reliant on the success of its product pipeline.
  • Supply Chain Disruptions: Any disruptions in the supply chain could delay clinical trials and product development.
  • Competition: Intense competition in the biopharmaceutical sector poses a constant challenge.

Recent Developments

  • Clinical Trial Progress: NextCure has reported promising interim results from ongoing clinical trials of NC318 and NC410, demonstrating potential efficacy in treating advanced cancers.
  • Pipeline Expansion: The company recently announced the initiation of clinical trials for NC762, targeting B7-H4.
  • Strategic Partnerships: NextCure has entered into new collaborations with leading academic institutions to advance its research efforts.
  • COVID-19 Impact: Like many companies, NextCure faced challenges during the COVID-19 pandemic, including delays in clinical trials. However, the company has since resumed normal operations.

Investment Considerations

Strengths

  • Innovative Pipeline: NextCure’s focus on novel immunomedicines positions it as a leader in the immunotherapy space.
  • Proprietary Technology: The FIND-IO™ platform provides a competitive edge in target discovery.
  • Experienced Leadership: The company is led by a team of seasoned professionals with a proven track record.
  • Collaborative Approach: Strategic partnerships enhance the company’s research capabilities.

Risks

  • Early-Stage Company: As a clinical-stage company, NextCure has yet to commercialize any products, making it a high-risk investment.
  • Regulatory and Clinical Risks: The success of the company’s pipeline depends on regulatory approvals and clinical trial outcomes.
  • Financial Uncertainty: NextCure relies on external funding and partnerships to sustain its operations.

Conclusion

NextCure, Inc. is at the forefront of immunomedicine, leveraging its innovative FIND-IO™ platform to develop novel therapies for cancer and immune-related diseases. While the company faces significant risks as a clinical-stage biopharmaceutical firm, its robust pipeline, experienced leadership, and strategic collaborations position it for long-term success. Investors should weigh the potential rewards against the inherent risks when considering NextCure as an investment opportunity.